“…Tyro3, Axl, and Mer are overexpressed in numerous cancers, including myeloid and lymphoblastic leukaemias, melanoma, breast, lung, colon, liver, gastric, kidney, ovarian, uterine, and brain cancers [2,6]. TAM receptor induction in tumour cells predominately promotes survival, chemoresistance and motility [2,6]. Inhibition of TAM kinases stimulates antitumour immunity, reduces tumour cell survival, enhances chemosensitivity and diminishes metastatic potential [2,6].…”